SearchDictionaryMobileLogin

Suzanne Oparil Selected Research

Hypertension (High Blood Pressure)

08/2008Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy.
06/2008Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.
04/2008Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
02/2008Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension.
01/2008Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan - amlodipine combination.
09/2007Renin inhibitors in the management of hypertension.
07/2007Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
03/2007Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
02/2007Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
01/2007The role of endothelin-1 in human hypertension.
12/2006Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.
11/2005Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
09/2005The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
04/2005Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
04/2005Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
03/2005The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
02/2005Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
01/2005Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide.
01/2005Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
09/2004Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
09/2003Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
09/2002Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
09/2002Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
03/2002Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
03/2002Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
03/2002Hormone replacement therapy and hypertension.
02/2002Sex hormones and hypertension.
02/2002Blood pressure and NaCl-sensitive hypertension are influenced by angiotensin-converting enzyme gene expression in transgenic mice.

Articles by Research Topic

Disease

28Hypertension (High Blood Pressure)
08/2008 - 02/2002
9Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
08/2008 - 09/2002
5Anoxia (Hypoxia)
07/2008 - 08/2003
3Stroke (Strokes)
01/2007 - 01/2005
2Albuminuria
02/2005 - 09/2004
1Cardiomegaly (Heart Hypertrophy)
01/2005
1Inflammation
10/2003
1Cardiovascular Diseases (Cardiovascular Disease)
10/2003
1Vascular Diseases (Vascular Disease)
08/2003
1Pulmonary Hypertension (Ayerza Syndrome)
12/2002

Drug/Important Bio-Agent (IBA)

18Losartan (Cozaar)FDA Link
08/2008 - 03/2002
9Atenolol (Tenormin)FDA LinkGeneric
09/2005 - 03/2002
3AldosteroneIBA
06/2008 - 09/2003
3Hydrochlorothiazide (Esidrix)FDA LinkGeneric
01/2007 - 01/2005
2valsartan (Vals)FDA Link
07/2007 - 03/2007
2Endothelin-1 (Endothelin 1)IBA
05/2007 - 01/2007
2AngiotensinsIBA
11/2005 - 01/2005
2Endothelin A ReceptorIBA
08/2003 - 12/2002
1Transforming Growth Factor beta (TGF-beta)IBA
07/2008
1olmesartanIBA
01/2008
1Amlodipine (Norvasc)FDA LinkGeneric
01/2008
1ReninIBA
09/2007
1aliskirenFDA Link
07/2007
1CollagenIBA
05/2007
1olmesartan medoxomil (Votum)FDA Link
03/2007
1irbesartanFDA LinkGeneric
12/2006
1Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA
02/2006
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
11/2005
1Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
09/2005
1OsteopontinIBA
10/2004
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
10/2004
1eplerenone (Inspra)FDA LinkGeneric
09/2003
1Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
08/2003
1Gonadal Steroid Hormones (Sex Hormones)IBA
02/2002
1Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
02/2002

Therapy/Procedure

2Hormone Replacement Therapy (Therapy, Hormone Replacement)
10/2003 - 03/2002